Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Diabetes Mellitus, Type 2 2Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Disease 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Sulfonylurea Compounds × 1 year × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

NCT05663515 2026-06-02

EXCEED

AstraZeneca

Recruiting
24,000 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡